Journal article
Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design
Abstract
BACKGROUND: The prognostic impact of response to prior chemotherapy independent of performance status (PS), hemoglobin (Hb), liver metastasis (LM), and time from prior chemotherapy (TFPC) in the context of second-line therapy for advanced urothelial carcinoma (UC) is unknown.
METHODS: Six phase II trials evaluating second-line therapy (n = 504) were pooled. Patients who received prior therapy for metastatic disease were eligible for analysis if …
Authors
Pond GR; Bellmunt J; Fougeray R; Choueiri TK; Qu AQ; Niegisch G; Albers P; Di Lorenzo G; Salhi Y; Galsky MD
Journal
Clinical Genitourinary Cancer, Vol. 11, No. 4, pp. 495–500
Publisher
Elsevier
Publication Date
December 2013
DOI
10.1016/j.clgc.2013.04.025
ISSN
1558-7673